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PULMONARY HYPERTENSION (PH) is a challenging
disease to treat and is associated with a great degree of morbidity and mortality. When a right ventricle, which is accustomed
to operating at low pressure, faces the increased afterload that
is conferred with PH, especially in the acute setting, it is prone
to failure and ultimately can result in hemodynamic collapse.
The normal physiologic changes of pregnancy, particularly
increased blood volume, lower systemic vascular resistance
and systemic blood pressure, and increased cardiac output, are
particularly deleterious in the patient with PH. Here, the
authors describe a case of a woman who was diagnosed with
severe PH during pregnancy and was safely navigated through
a cesarean section and the subsequent postpartum period.
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Case Report
A 21-year-old woman, G1P0, with no known significant past
medical history, presented to a community hospital at gestational age 26 weeks and 5 days, with a chief complaint of
blood in her sputum. Further questioning revealed a 2-week
history of low-volume hemoptysis. Her family history also
was notable for the death of her mother while giving birth to
her younger sibling due to heart failure. A limited workup was
performed, and the patient eventually was discharged home
with the working diagnosis of a Mallory-Weiss tear.
At a gestational age of 28 weeks, she presented to the same
community hospital with dyspnea on exertion, persistent
coughing, and ongoing hemoptysis. A transthoracic echocardiogram (TTE) was obtained, which was notable for a left ventricular ejection fraction of 55%, right atrial and ventricular
enlargement, and moderate-to-severe tricuspid regurgitation
(TR). Importantly, McConnell’s sign was present, and the estimated pulmonary artery systolic pressure (PASP) was greater
than 100 mmHg. Given the increased risk for thrombotic
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Fig 1. Transthoracic echocardiography apical 4-chamber view showing right ventricular dilation.

complications during pregnancy, a pulmonary embolism was
suspected to be the cause of these findings. An unfractionated
heparin infusion was started, and a computed tomography scan
of the chest was performed. The scan was abnormal, showing
multifocal opacities throughout the bilateral lung fields; however, there was no evidence of pulmonary embolism. The
patient then was transferred to the authors’ tertiary care center
for further workup and management.
Upon arrival to the authors’ institution, inhaled epoprostenol
was initiated at 50 ng/kg/min via a high-flow nasal cannula.
Daily diuresis also was commenced. A right-heart catheterization was performed, which showed a right atrial pressure of 15
mmHg, a pulmonary artery pressure (PAP) of 88/41 mmHg
(mean 61 mmHg), a pulmonary capillary wedge pressure of 14
mmHg, a cardiac output/index of 8.2/4 L/min, a pulmonary
vascular resistance of 5.7 Wood units, and a systemic vascular
resistance of 5 Wood units. The inhaled epoprostenol was discontinued, and intravenous treprostinil was initiated at 2 ng/
kg/min, with plans to increase the dose by 1 ng/kg/min every
12 hours. The treprostinil eventually would be titrated up to 22
ng/kg/min at the time of delivery, and daily diuresis continued.
A multidisciplinary meeting was held with clinicians from
the PH/heart failure cardiology service, cardiac surgery, cardiac anesthesia, maternal-fetal-medicine, and high-risk obstetrics teams. A plan was formulated to deliver the fetus via
cesarean section at gestational age 32 weeks and 6 days, utilizing slowly titrated epidural anesthesia and prophylactic

femoral arterial and venous cannulation for the prospect of
peripartum extracorporeal membrane oxygenation (ECMO). A
repeat TTE was performed, which showed a severely dilated
right ventricle (Fig. 1 and 2) with mildly decreased function,
severe TR, an estimated PASP of 98 mmHg (Fig 3), and a left
ventricular ejection fraction of 65%.
On the day of delivery, the patient was brought to the operating room, and a right radial arterial catheter was placed. She
then was placed into the seated position for the insertion of a
lumbar epidural catheter without sedation. After placement of
the epidural, inhaled epoprostenol was initiated at 50 ng/kg/
min via a high-flow nasal cannula. The epidural slowly was
dosed with 0.5% bupivacaine, which was given in 5- mL aliquots to prevent any abrupt hemodynamically significant
changes. She then was placed in a semisupine with a slight
reverse Trendelenburg position because she could not tolerate
lying flat due to dyspnea. The cardiac surgical team then
inserted a femoral arterial catheter and femoral venous sheath
in the event that a swift initiation of venoarterial ECMO (VA
ECMO) was necessary. A 9-French introducer was placed in
the right internal jugular vein to serve as large-bore access and
to facilitate central venous pressure monitoring. Two mg of
midazolam were given during the placement of the femoral
and internal jugular lines for anxiolysis, and 100 mg of fentanyl also were given during the procedure.
An epinephrine infusion was initiated prior to incision to
support right ventricular contractility. Phenylephrine and
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Fig 2. Transthoracic echocardiography parasternal short-axis view showing right ventricular dilation.

vasopressin infusions were used to treat reductions in afterload. Numerous intravenous boluses of these medications also
were required throughout the procedure. Overall, the procedure was tolerated well, with an estimated blood loss of
800 mL.
After the procedure, the patient was brought to the intensive
care unit for further monitoring, with the femoral arterial and
venous lines in place. Inhaled epoprostenol and intravenous
treprostinil were continued, with a plan to transition to oral
tadalafil. Additionally, intravenous infusions of epinephrine
and vasopressin were required. On postoperative day 1, her
epidural was removed, and a TTE showed a severely dilated
right ventricle with moderately decreased function, moderate
TR, and an estimated PASP of 117 mmHg. The TTE on postoperative day 2 was largely unchanged, with an estimated
PASP of 125 mmHg. On postoperative day 4, her femoral lines
were removed. Vasopressors were weaned completely by postoperative day 6. On postoperative day 15, the right atrium and
ventricle still were severely dilated, with moderately decreased
right ventricular function, and an estimated PASP of 91
mmHg. Tadalafil, bumetanide, and treprostinil were continued
throughout the hospital stay.
Discussion
PH in pregnancy confers high morbidity and mortality. Historically, the incidence of maternal mortality reached as high

as 30%-to-56%.1 More recent studies reported improved outcomes, which may represent improvements in medicine, such
as the availability of epoprostenol in 1996; however, this also
could represent a publication bias by which the cases with
favorable outcomes were being reported. Even if outcomes
have improved, morbidity and mortality remain high enough
that groups like the Pulmonary Vascular Institute recommend
that women with PH avoid pregnancy. In this case conference,
the patient was not known to have PH until she was more than
halfway through pregnancy with a viable fetus. The management of this patient required input and coordination of care
from a multidisciplinary team, which ultimately resulted in a
successful outcome.
Historically, PH was defined as a resting mean PAP of 25
mmHg.2 In 2019, however, the sixth World Symposium on
Pulmonary Hypertension recommended that the cut-off be
lowered to 20 mmHg. PH also can be divided into 5 groups
based on etiology. Group 1 refers to pulmonary arterial hypertension, which has many possible causes, including idiopathic.
Group 2 is PH due to left-heart disease, such as left ventricular
failure or valvular heart disease. Groups 3, 4, and 5 represent
patients who have PH due to lung disease, pulmonary arterial
obstructive processes, such as pulmonary embolism, or unclear
mechanisms, respectively.2 The term “precapillary PH”
encompasses all groups except group 2. Postcapillary PH,
however, only includes either group 2 or group 5. Interestingly, it is possible for a patient to exhibit signs of both
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Fig 3. Continuous-wave Doppler tracing obtained from a transthoracic echocardiography apical 4-chamber view showing a peak tricuspid regurgitation pressure
gradient of 83 mmHg. The right atrial pressure was estimated to be 15 mmHg, which suggested that the estimated right ventricular systolic pressure was 98
mmHg.

precapillary and postcapillary PH; these patients typically are
from either group 2 or group 5.
While echocardiography initially raised suspicion for severe
pulmonary hypertension, right-heart catherization is the gold
standard for diagnosis.3 In addition to measuring the pulmonary arterial pressure, the pulmonary capillary wedge pressure
should be obtained, and the pulmonary vascular resistance
should be calculated. Precapillary pulmonary hypertension
typically is characterized by a mean pulmonary arterial pressure 20 mmHg, a pulmonary capillary wedge pressure 15
mmHg, and a pulmonary vascular resistance 3 Wood units.
In contrast, patients with postcapillary pulmonary hypertension demonstrate a mean pulmonary arterial pressure 20
mmHg, a pulmonary capillary wedge pressure >15 mmHg,
and a pulmonary vascular resistance <3 Wood units.2 If a
patient has combined precapillary and postcapillary pulmonary
hypertension, however, they may exhibit a mean pulmonary
arterial pressure 20 mmHg, a pulmonary capillary wedge
pressure >15 mmHg, and a pulmonary vascular resistance 3
Wood units. The patient in this case exhibited a pulmonary
capillary wedge pressure of 14 mmHg and a pulmonary vascular resistance of 5.7 Wood units, consistent with precapillary
pulmonary hypertension.
Typically, nonpregnant patients with PH commonly present
with fatigue and dyspnea on exertion due to reduced cardiac

output and, consequently, decreased oxygen exchange.
Because fatigue and exertional dyspnea are common complaints for healthy pregnant women as well, the diagnosis can
be delayed in pregnant patients.4 Pregnancy-related changes
eventually can exacerbate symptoms, such as dyspnea on exertion, progressing to dyspnea at rest. In contrast to healthy pregnant women who can accommodate the increased cardiac
output with a decreased pulmonary vascular resistance, those
with diseased pulmonary vasculature will develop increased
pulmonary vascular pressures. Unfortunately, the increased
pulmonary vascular resistance in these patients ultimately may
prevent the necessary increase in cardiac output for pregnancy.
As the disease progresses, right- heart failure may develop due
to acute volume and pressure overload. At this stage, patients
may begin to complain of right-heart failure symptoms, such
as hepatomegaly, swollen ankles, ascites, or chest pain from
right-heart ischemia. Heart failure symptoms typically are
late-stage signs of disease progression.5 It was fortunate that
the patient in this case sought treatment for her symptoms. Initially, however, pulmonary embolism was thought to be the
main pathology.
It was necessary to consider pulmonary embolism in the differential diagnosis because pregnancy induces a prothrombotic
state to help prevent significant postpartum hemorrhage. A
hypercoagulable state is maintained by increasing clotting
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factors V, VII, VIII, IX, XII, fibrinogen, and increased platelet
aggregation. Additionally, due to the increased levels of plasminogen activator inhibitor, fibrinolysis also is reduced, ultimately contributing to the prothrombotic state.6
Simultaneously, due to hormonal influence and the rapidly
growing uterus, lower extremity veins increase in diameter
and decrease in flow. These expected physiologic changes that
accompany pregnancy greatly increase the risk for deep vein
thrombosis.7
Venous thromboembolism is a feared and major complication during pregnancy and occurs at a frequency of 0.5-to-2.2
per 1000 pregnancies.8 The increased risk is present during all
trimesters of pregnancy, but is highest in the last. Thrombosis
risk also extends into the postpartum period for about 3 weeks
before it declines.9 Deep vein thrombosis is more common
during pregnancy than pulmonary embolism. Pulmonary
embolism risk, however, is higher during the postpartum
period and continues to be one of the leading causes of maternal death in pregnancy.10
Given this increased risk for thromboembolic complications, an acute pulmonary embolus initially was suspected to
be the cause of this patient’s symptoms. This diagnosis also
was consistent with echocardiogram findings, such as
McConnell’s sign. Because there was a concern for pulmonary
embolism, the patient was immediately anticoagulated. However, the computed tomography scan ruled out a pulmonary
embolus. With no active thrombosis or occlusive disease process, PH group 4 was ruled out. The patient did not have any
prior history of left ventricular or valvular failure (group 2),
and she also did not have any chronic respiratory diseases
(group 3). Overall, the preponderance of information, including the right-heart cardiac catheterization data, suggested that
group 1 PH was most likely.
Once the diagnosis of PH was made, it became imperative to
closely monitor the patient’s hemodynamic status as pregnancy progressed. While morbidity and mortality related to
PH in pregnancy have improved according to recent literature,
thet nevertheless remain a concern. In the registry of pregnancy and cardiac disease, 151 patients with PH were identified between 2008 and 2014.11 Of these patients, 112 (74.2%)
had group-2 PH, whereas 39 (25.8%) had group 1. The diagnosis of PH was known in 88 patients prior to pregnancy. Right
ventricular systolic pressures were 30-to-50 mmHg in 90
patients, 50-to-70 mmHg in 43 patients, 70-to-90 mmHg in 8
patients, and >90 mmHg in 10 patients. While no deaths
occurred during pregnancy, there were 7 known deaths in the
6 months after delivery. Three of the 7 deaths were in patients
with idiopathic pulmonary arterial hypertension. Fetal complications included premature delivery in 21.7% of patients, low
birth weight in 19.0%, and fetal mortality in 2%. While this
study had limitations, such as unknown timing of PH in 25%
of patients, the maternal mortality was considerably less than
previously reported.11
In a smaller series, Meng et al. analyzed 49 pregnant women
with PH between 2001 and 2015.12 Severe PH was present in
27 patients, whereas mild PH was present in the other 22.
Twenty-six women required advanced therapy (vasoactive
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medications, extracorporeal membrane oxygenation), which
was more common in the group with severe PH. The documentation of delivery was present in 41 patients, with 54% of
patients undergoing cesarean section. The majority of patients
received neuraxial anesthesia for either cesarean section or
vaginal delivery, without any anesthetic complications. Overall, the mortality was 16% (8 of 49), with the majority of the
deaths occurring in patients with group-1 PH. Notably, all
deaths occurred after delivery, including all 6 patients in
whom ECMO was used.12 While there were no neonatal
deaths, 26 of 41 deliveries were preterm, and 23.5% of neonates with a documented birth weight were small for gestational age.
A recent study with surprisingly low mortality was published by Thomas et al.13 The National Inpatient Sample was
analyzed, and 1,519 pregnant women with PH were identified
between 2003 and 2012. Despite including patients with congenital heart disease, valvular heart disease, and cardiomyopathy, mortality was only 0.8% (12 of 1,519). However, major
adverse cardiac events still occurred in 24.8%, which predominantly were driven by heart failure and arrhythmias. Nevertheless, the low rate of mortality was in stark contrast to prior
data, such as a systematic review by Bedard et al. demonstrating mortality rates of 38% in a historic cohort and 25% in a
more recent cohort, and an older study by Weiss et al., reporting a mortality of 30% in primary PH and 56% in secondary
vascular PH (1978-1996).14,15 Overall, it seems that maternal
mortality is lower in the more recent literature, although
maternal morbidity remains a concern.
Given the possibility of hemodynamic compromise during
delivery, consideration was given to ECMO as a rescue strategy. Before cesarean section, the patient’s severely elevated
PAP and increased plasma volume secondary to the pregnancy
already were placing a significant amount of strain on the right
ventricle. Intraoperatively, volume shifts, along with potential
increases in pulmonary vascular resistance due to hypoxia,
hypercarbia, acidemia, or pain, could place the right ventricle
at high risk for acute failure. Therefore, the perioperative care
team elected to place predelivery femoral vein and artery catheters. These catheters would be utilized for the institution of
VA ECMO if acute hemodynamic instability occurred during
delivery. The catheters were to remain in place for several
days postpartum as well. An important consideration when
deliberating on ECMO as a rescue device is determining
whether the underlying condition is treatable and if the condition is recoverable. As previously discussed, patients with PH
have difficulty tolerating the physiologic changes associated
with pregnancy. Because pregnancy is of limited duration, and
this patient population typically is younger and often without
significant comorbidities, the right ventricle should be recoverable.
Unfortunately, there is a lack of supportive evidence for the
use of ECMO in the obstetric population. Data supporting
ECMO use in the pregnant population primarily are focused
on venovenous ECMO (VV ECMO) for respiratory support
rather than VA ECMO. Moore et al. searched outcomes for
pregnant patients who were supported with ECMO during their
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pregnancy. The study looked at 45 patients, but only 4 were on
VA ECMO, while the rest were supported with VV ECMO.
The overall maternal survival rate was 77.8%, while the fetal
survival rate was 65%.16 In another study, Agerstrand et al.
similarly examined 18 patients who were placed on either VV
or VA ECMO, but only 4 were supported during pregnancy
(VA ECMO or VAV ECMO), and the remaining patients were
supported postpartum.17 Indications for ECMO included PH
(n = 1), pulmonary embolism (n = 2), and amniotic fluid embolus (n = 2), but the majority were acute respiratory distress syndrome on VV ECMO support. Overall, maternal survival was
88.9% (16 of 18), and fetal survival was 77.8% (14 of 18). Of
the 4 patients who were placed on ECMO support during pregnancy, 2 delivered while on ECMO support. Fetal complications were not attributed to ECMO support. Complications
during the study included bleeding in 6 patients, and 14
patients required blood transfusions. One patient required a
lower extremity amputation secondary to cannulation siteassociated limb ischemia. One patient with PH was supported
on VA ECMO during pregnancy and successfully delivered.
However, after delivery, disseminated intravascular coagulation ensued, along with abdominal compartment syndrome,
which required an exploratory laparotomy. Despite serious
complications, she eventually was weaned off support and successfully discharged from the hospital.17
Overall, this case conference emphasizes the significance of
PH in pregnancy. PH is a contraindication to pregnancy
because of its associated high morbidity and mortality. Patients
with a diagnosis of PH are counseled appropriately to help prevent harm to themselves. Nevertheless, some patients will
knowingly take the risk of pregnancy. Others, however, may
not yet know they have PH and may be asymptomatic due to
compensatory mechanisms. The patient in this case conference
was otherwise healthy and did not carry a diagnosis of PH until
the changes of pregnancy ensued, and she was unable to compensate anymore. While ECMO was not needed to rescue this
patient, the evidence supporting its use for this population is
minimal. Patients who might require such support should be
transferred to centers with experience, resources, and dedicated teams to initiate ECMO, if necessary. The decision to
proceed with ECMO requires careful consideration, and it
should be considered only in patients with recoverable conditions. The risks of ECMO must be weighed against the benefits
it will provide for the patient.
Expert Commentary (Dr. Kiers, Dr. Younger, and Dr.
Sanders)
Providing anesthesia to patients who have PH is a medical
challenge, especially when treating pregnant women who have
PH. In parturients, PH confers an increased risk of morbidity
and mortality to both the mother and the fetus.18-22 Historically, mortality rates for pregnant women with PH have ranged
from 30%-to-50%.1,14,19,23,24 However, more current studies
suggest that maternal mortality rates for women with PH have
decreased in recent years to 12%-to-30%, in part due to
advancements in modern medicine, an increased focus on early

treatment with close monitoring, and the use of multidisciplinary medical teams for these at-risk patients.11,12,14,20,22,24
However, even with these improvements in outcomes, some
experts continue to recommend against pregnancy for women
with PH and may suggest that elective termination be
offered.12,18,19,25 Considering the high risk of decompensation
and death for pregnant women with PH, it is essential that
each patient be provided an individualized, tailored anesthetic
approach. The case presentation highlighted here considered a
successful cesarean delivery with epidural anesthesia in a
woman with severe PH. This case demonstrated how the use
of a specialized multidisciplinary team and individualized
planning can lead to favorable outcomes for these at-risk
patients.
Historically, PH has been defined as a mean PAP 25
mmHg at rest as measured via right-heart catheterization.
Newer guidelines from the sixth World Symposium on Pulmonary Hypertension recommend a revised PAP cut-off of 20
mmHg.2,25,26 PH has many causes, which are grouped by
shared clinical features and pathophysiology. The current
group classifications of PH are as follows: Group-1 PH is
caused by idiopathic and familial causes or specific drugs and
toxins; Group-2 PH is due to left-sided heart disease; Group-3
PH occurs as a consequence of lung disease or hypoxia;
Group-4 PH is caused by thromboembolism; and Group-5 PH
is due to multifactorial or unknown causes.2,25,26 When possible, the underlying cause of PH should be identified because it
has significant implications for treatment approaches, including anesthetic plans. Recent studies suggest that the causes of
PH also may affect mortality rates.11,22 Although the presented
case did not specify the patient’s PH classification, she likely
had Group-1 PH, given that no alternative cause was identified.
The physiologic changes that occur during pregnancy have
been well-described. These changes affect nearly all organ systems and have significant effects on women with PH.1,23,24,27
Hemodynamic changes occur early in pregnancy, with significant increases in cardiac output and plasma volume starting in
the first trimester.25,27 This highlights how quickly systemic
changes occur in pregnancy and helps clarify how pregnancy
in undiagnosed patients may lead to the development of symptoms and an ultimate diagnosis of PH.25,27 The patient presented in this case conference fit this picture, as she had no
symptoms of PH before pregnancy. Patients presenting with
new symptoms suggestive of PH should be evaluated with
echocardiography and, when applicable, right-heart
catheterization.18,25,28
The decision to use advanced therapies to treat pregnant
women who have PH should be case-specific. Current
advanced therapies include calcium-channel blockers, prostaglandins, phosphodiesterase-5 inhibitors, and endothelinreceptor antagonists.1,19,20,29 Advanced therapies should be
initiated, continued, or escalated based upon the etiology of
PH and the patient’s clinical presentation.18,20 Among therapies for qualifying patients with significant right ventricular
dysfunction, intravenous epoprostenol has been widely
described.1,28 For some patients, inhaled prostaglandins may
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be suitable, with the acknowledgment that switching to intravenous therapy may be required in cases of clinical
worsening.1,28 The patient in this case was started on inhaled
treprostinil therapy, with a subsequent change to intravenous
epoprostenol in the antepartum period; however, she eventually had a successful delivery while she was taking inhaled treprostinil. It is critical to note that endothelin-receptor
antagonists, such as bosentan, are teratogenic, and, therefore,
should be discontinued in pregnant women when possible to
avoid potential developmental harm.1,25 Other pertinent therapies typically used for patients with PH include anticoagulation with heparin, fluid restriction, and diuretics for
intravascular fluid management.1,19,21,24,25
Given the complexity of treating pregnant women who have
PH, one of the most important therapeutic steps involves the
formation of a specialized, collaborative multidisciplinary
team.14,18,20,22,23,25,29 Healthcare providers with expertise in
PH, advanced obstetrics and maternal-fetal medicine, and neonatology, as well as obstetric and cardiothoracic anesthesia,
are key members of these teams.1,20,23,25,29 In this case report,
the patient was transferred to a tertiary-care center, where a
multidisciplinary team was assembled, and a detailed plan for
delivery was constructed.
For delivery of the fetus within the context of maternal PH,
the current professional consensus is that cesarean delivery is
the preferred route.1,29 While vaginal delivery is associated
with the benefits of decreased risks of bleeding, infection, and
thromboses, there are multiple negative aspects to this delivery
route pertinent to women with PH.1,14,23,29 These include
potential worsening of already elevated pulmonary pressures,
a decrease in venous return with Valsalva maneuvers,
increased risk of significant pain resulting in sympathetic stimulation, and increased risk of acidosis, all of which can place
the PH patient at high risk for cardiovascular collapse.1,14,23,29
For these reasons, early and effective analgesia is of paramount importance for patients with PH who undergo vaginal
delivery.1,23 Assisted vaginal delivery also may be beneficial
by reducing maternal effort.25
In keeping with the general recommendation for cesarean
delivery, recent analyses have reported that most pregnant
women with PH undergo cesarean deliveries.1,11,14,19,20 In these
patients, planned cesarean delivery has the benefit of allowing
the provider team to determine the timing of delivery during
daytime hours, which provides the assurance that adequate staff
and resources are available if needed.19,20,23,29 Furthermore,
cesarean delivery avoids the potentially deleterious effects of
reduced preload and cardiac output that are associated with the
use of the Valsalva maneuver during vaginal delivery.1,14,23,29
When cesarean delivery is performed, neuraxial anesthesia
is preferred over general anesthesia (GA).1,23 A review by
Bedard et al. found that pregnant women with PH who
received GA were 4 times more likely to die than those who
underwent neuraxial anesthesia.14 While this seems to suggest
that neuraxial anesthesia is the optimal method of anesthetic
management during cesarean delivery, it is important to note
that selection bias may have limited the significance of these
observed results.14 For example, it is possible that GA may be
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required for acutely ill patients, which could explain poorer
outcomes.1,14 GA also may be required for instances in which
neuraxial anesthesia is contraindicated or rejected by the
patient.1,23 When GA is used for pregnant women with PH, it
is important that the anesthesiologist be aware that potentially
harmful effects of GA include cardiac depression from volatile
agents and changes in pulmonary pressures during laryngoscopy, intubation, and positive-pressure ventilation.1,14
When neuraxial anesthesia is deemed appropriate, epidural
anesthesia generally is considered the safest approach, as it
allows for a slow, incremental, low-dose administration of a
local anesthetic, which reduces the risk of acute hemodynamic
changes from sympathectomy.1,19 As an alternative, combined
spinal-epidural anesthesia is also a safe option when low-dose
intrathecal opioid or local anesthetic is used, because it provides a denser block along with the option of incremental dosing via the epidural.1,19,23 Spinal anesthesia, conversely, is
generally avoided, given the proclivity for sympathectomy.1
The patient highlighted in the presented scenario underwent a
slowly titrated epidural anesthetic, which likely aided in her
overall relative hemodynamic stability throughout the cesarean
procedure.
Regardless of the anesthetic approach taken, the period
immediately after delivery for women with PH is associated
with a significant risk for decompensation and hemodynamic
collapse.1,11,14,19,22,27,29 The physiologic changes that occur in
the immediate postpartum state include sudden relief of vena
caval compression, which results in increased preload, extravascular fluid volume shifts, and a massive increase in cardiac
output to 60%-to-80% of prelabor levels.1,23,27 These acute
hemodynamic changes may lead to right ventricular failure,
cardiorespiratory failure, and even sudden cardiac arrest in
patients with PH.1,23 Multiple reviews have reported the postpartum period to be particularly dangerous for women with
PH.11,14,19,22 A review by Sliwa et al. examined the outcomes
of 151 pregnant women with PH who were included in the
European Registry of Pregnancy and Heart Disease.11 While
those findings indicated that no deaths had occurred during
pregnancy, maternal death occurred in 3.3% of patients in the
immediate peripartum period up to 1 week postdelivery, and
2.6% of 78 follow-up patients had died within 6 months after
delivery.11 Another more recent study by Low et al. found that
while the maternal mortality rates of 12%-to-20% that they
observed were lower than those historically reported, depending on the cause of PH, 61% of maternal deaths occurred
within 0-to-4 days postpartum, with the cause of death occurring from right ventricular failure, cardiac arrest, PH crisis,
pre-eclampsia, and sepsis.22 Vasopressors, inotropes, and
advanced intravenous and inhaled PH treatments should be
available for use during delivery.1,22
Given the precariousness of delivery and the postpartum
state for women with PH, special monitoring and plans for stabilization in the setting of acute decompensation are
recommended.1,23 In general, patients should deliver at a care
center with access to intensive care units for both the mother
and neonate.1,12,23,29 Advanced hemodynamic monitoring with
an arterial line also is recommended, especially when PH is
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deemed severe.1,23 A central line may be used, especially as an
access point for expected vasoactive medication administration or intravenous pulmonary dilator therapy; however, there
is no clear consensus regarding the placement of a central line
within this context.1,23
Special acute interventions, such as ECMO, may be necessary for women with PH in the peripartum period.1,12,23,29,30
While many patients will not require ECMO, some risk factors
necessitating ECMO use include severe PH, severe right ventricular dysfunction, Eisenmenger syndrome, and World
Health Organization group-1 PH.23,29 Currently, there are no
guidelines regarding the use of ECMO in pregnant women
with PH. A recent systematic review by Naoum et al. showed
that there is a paucity of research regarding ECMO use for
pregnant women.30 One study that assessed 358 pregnant
women who had venoarterial, venovenous, or combined support, showed a maternal survival rate of 75.4% at 30 days postdelivery and 74.3% after 1 year.30 Observed complications
were relatively low, with 18.4% of patients developing moderate bleeding, 13.4% developing severe bleeding requiring surgical intervention, and 5.3% developing intracranial
neurologic morbidity.30 In regard to pregnant women with PH
specifically, the authors noted a survival rate of 50%, which
seems to be a significant improvement compared to 16.7% in
previous studies.30 Further studies regarding ECMO use are
needed to guide the best treatment strategies for pregnant
women with PH. Although there are no guidelines that recommend prophylactic ECMO cannulation for pregnant women at
this time, it can be considered a reasonable approach for
patients with severe PH, such as in the presented patient’s
case. Because ECMO has relatively low complication rates, it
is prudent that anesthesiologists discuss this option with
patients early in the course of treatment.30
Although several recent retrospective studies analyzing PH
during pregnancy have been done, several factors may limit
the utility of these findings. First, publication bias and minimal
reporting of adverse outcomes may limit an understanding of
true morbidity and mortality rates.1,11,14,20,24 Furthermore,
small sample sizes limited data collection and analysis.11 As
there are obvious moral implications to performing prospective studies on this vulnerable population, additional retrospective research will be needed to guide future treatment
optimization.11 In the presentation of this case, the authors
have demonstrated that, despite having a high risk for decompensation and death, pregnant women with PH can have favorable outcomes when they are treated by a specialized
multidisciplinary team and treated with advanced PH therapies. Also, the careful creation of contingency plans, such as
prophylactic ECMO cannulation, should be prepared for these
at-risk patients to prevent or treat acute hemodynamic collapse.
Expert Commentary (Dr. Knott and Dr. Fernando)
In this case conference, the authors discuss a case in which a
young woman was diagnosed with PH during pregnancy. She
previously was thought to be healthy until dyspnea, cough,

and hemoptysis prompted an investigation into the cause of
these symptoms. After severe PH was diagnosed, she required
a prolonged hospital stay to ensure close monitoring, administer treatment, and facilitate the delivery of the child, while
ensuring the appropriate cardiovascular resources were available for the mother should she experience cardiovascular collapse. In this commentary, the role of echocardiography in this
complex case is explored. First, however, it is imperative to
understand the altered physiology that occurs during pregnancy.
While it is not known how long this patient had PH, the
physiologic changes of pregnancy likely unmasked it. These
changes include an approximately 45% increase in blood volume, a 20%-to-25% increase in heart rate, increased stroke
volume, and an increase in cardiac output.27 Patients with preexisting PH may not have the capacity to manage the increased
blood volume and cardiac output, which subsequently can
overwhelm the right ventricle into failure.31 The decrease in
blood pressure that typically accompanies pregnancy27 also
can be problematic for patients with PH. Normally, the right
ventricle receives perfusion during both systole and diastole.
Patients with PH, however, have elevated right ventricular systolic pressures, which can result in perfusion that is limited to
diastole.32 Overall, the physiologic changes of pregnancy
likely contributed to the manifestation of symptoms in this previously asymptomatic patient.
At 28-weeks’ gestation, persistent dyspnea, cough, and
hemoptysis prompted an echocardiographic evaluation. It is
worth noting that there are several echocardiographic changes
that are normally observed during pregnancy. These include
increases in left ventricular dimensions, left ventricular diastolic and systolic volumes, as well as left ventricular wall
thickness.33 The left ventricle also develops more of a spherical shape, as indicated by a decrease in the sphericity index.
However, in the context of PH, the changes in the morphology
of the right ventricle induced by pregnancy are perhaps more
concerning. Ducas et al. studied 34 pregnant women who
underwent TTE and cardiac magnetic resonance imaging in
the third trimester and postpartum.34 They demonstrated
increases in right ventricular end-diastolic diameters during
the third trimester by both imaging modalities without changes
in right ventricular function. Notably, the postpartum values
were used as the “baseline.” In another study, Del Prado Diaz
et al. compared 43 pregnant women to 19 nonpregnant women.
They also demonstrated increases in right ventricular diameters; in contrast to the prior study, they noted decreases in
some markers of right ventricular function as the pregnancy
progressed.35 Specifically, the S’ velocities obtained by tissue
Doppler imaging did not decrease during pregnancy, but the
right ventricular fractional area change and tricuspid annular
plane systolic excursion (TAPSE) measurements did decrease.
Despite this decrease, however, right ventricular markers for
systolic function still were within the normal range. A prospective cross-sectional study by Melchiorre et al. yielded similar
results.36 In this study, a group of 50 healthy, nonpregnant
women was used as controls. Four similarly sized groups of
nulliparous pregnant women, ranging from 95-to-109
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participants, were recruited at various stages of pregnancy.
Compared to the nonpregnant controls, S’ velocities did not
significantly differ, and although TAPSE still was within the
normal range, it was significantly lower at term.36 Collectively, these studies demonstrated that in healthy pregnant
patients, the right ventricle may dilate and may experience
some dysfunction. In the patient with preexisting PH, however,
right ventricular dilation and dysfunction already may exist,
and the stress of pregnancy may threaten the ability of the right
heart to further compensate.
In this patient, the degree of right ventricular enlargement
on the echocardiogram at 28 weeks was not specified by the
authors. Nevertheless, the development of moderate-to-severe
TR was concerning. While the valvular incompetence was
unfortunate, it did facilitate the diagnosis of the patient’s PH.
Traditionally, the velocity of the TR jet (v) is measured using
continuous-wave Doppler, and the right ventricular systolic
pressure is estimated by using the following equation:
4v2 + right atrial pressure.37 If she did not have sufficient TR
to obtain this measurement, it is possible her diagnosis could
have been missed or delayed. While some may assume that
patients with PH will have a TR velocity that is easily measurable, this is not necessarily the case. In a retrospective study
by O’Leary et al., 1,262 patients who had a TTE within 2 days
of a right-heart catheterization that diagnosed PH were studied.38 PH was diagnosed in 47% of patients who did not have a
reported TR velocity. This included some patients with mean
PAPs approaching 60-to-70 mmHg. Overall, the lack of a
reported TR velocity only had a negative predictive value of
53% to exclude the diagnosis of PH. Interestingly, larger left
atrial diameters and right ventricular dysfunction were associated with the group, from which TR velocities were not
reported, and PH due to left-heart disease was the most prevalent type.38
If this patient did not have significant TR but PH was
strongly suspected, the pulmonary artery acceleration time
also can be used (PAAT). Yared et al. used PAAT by placing
the pulsed-wave Doppler sample gate at the level of the pulmonic valve annulus and subsequently measuring the time
from the onset of right ventricular ejection to the peak.37 The
PASP then can be estimated based on the equation
log10(PASP) = 0.004 (PAAT) + 2.1. This method is not without limitations, as the PAAT may be affected by external factors, including right ventricular function. Abnormal right
ventricular function, for example, can result in a higher
PAAT.
In addition to the estimated right ventricular systolic pressure being greater than 100 mmHg, the TTE also was concerning for McConnell’s sign. McConnell’s sign describes a
particular pattern of right ventricular motion in which there is
akinesis of the mid-free wall but preserved motion of the right
ventricular apex that is associated with acute pulmonary embolism.39 It is not entirely clear why such a pattern manifests, but
several theories exist. These include (1) ischemia, specifically
in the free wall; (2) wall stress that results in a change in right
ventricular shape; and (3) transmitted movement from a hyperdynamic left ventricle that mimics right ventricular apical
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contraction.39 Interestingly, despite the classic teaching of this
sign, it may not be very sensitive. In a retrospective study by
Kurnicka et al., of 511 patients with acute pulmonary embolism, only 101 (19.8%) demonstrated McConnell’s sign.40 A
review that pooled data from 2 other studies found a similar
sensitivity of 19% but also demonstrated a high specificity of
98%.41 Another potential echocardiographic finding is the “60/
60” sign. This refers to the presence of both a PAAT <60 ms
and a TR jet pressure gradient <60 mmHg.39 In the previously
mentioned study by Kurnicka et al., the 60/60 sign was seen
only in 66 of 511 patients (12.9%).40 These signs performed
more favorably in a study that specifically examined patients
with submassive or massive acute pulmonary embolus.42 In
this study, the sensitivity and specificity were 52% and 97%
for McConnell’s sign, respectively, and 51% and 96% for the
60/60 sign, respectively. Notably, both of these signs were outperformed by early systolic notching, a pattern seen on the
waveform obtained by placing the pulsed-wave Doppler sample gate in the right ventricular outflow tract, which had a sensitivity and specificity of 92% and 99%, respectively. In
contrast, the sensitivities for McConnell’s sign, 60/60 sign,
and early systolic notching were only 7.1%, 7.0%, and 2.3%,
respectively, in patients with subsegmental pulmonary
emboli.42 Overall, both McConnell’s and 60/60 signs seem to
have poor sensitivity but perform better in patients with more
extensive pulmonary emboli. In patients with a submassive or
massive pulmonary embolus, however, early systolic notching
may be the more sensitive and specific sign.
Echocardiography also can be used to monitor the patient in
the perioperative period. During a cesarean section, this patient
received a neuraxial anesthetic, which can result in hypotension. In addition, the autotransfusion of blood from the uterus
immediately after delivery potentially could result in right ventricular failure. Kumaresan et al. studied 98 pregnant patients
who underwent delivery by cesarean section using a spinal
anesthetic comprised of 11.25 mg of 0.75% hyperbaric bupivacaine, with 25 mg of fentanyl and 250 mg of morphine.43 All
patients received a preoperative TTE immediately before surgery, as well as within the first 2 hours after surgery. Notably,
the right ventricular function was depressed at baseline, as evidenced by a mean fractional area change of 24.0%. While no
significant difference was found in the right or left ventricular
function before versus after surgery, the right ventricular
image quality was only sufficient in 81% of patients prior to
surgery and in 67% of patients after surgery. Additionally,
because the heart may be in a different position before and
after surgery due to the delivery of the baby, it may result in
images that are not necessarily comparable.43
Presumably, transesophageal echocardiography would have
been used intraoperatively if GA were chosen. While transesophageal echocardiography was not possible under a neuraxial
anesthetic in this awake patient, a focused TTE examination
could have been performed in cases of hemodynamic instability or dyspnea to help narrow the differential.44 TTE is a noninvasive, relatively low-risk procedure that pregnant women
are accustomed to and can be performed on awake patients.
The subcostal view may be best reserved for the postpartum
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period because the supine position is required and may predispose the patient to aortocaval compression. In contrast, the left
lateral position to avoid aortocaval compression may facilitate
obtaining parasternal and apical views. However, apical views
may be limited due to increased breast size. A focused TTE
examination can provide information on the left ventricular
ejection fraction, which may be impaired due to peripartum
cardiomyopathy. Additionally, the presence of pericardial
effusion or aortic dissection also can be evaluated. In the
patient with PH, increased attention needs to be dedicated to
evaluating the right ventricle. In particular, an assessment of
structure, as well as the systolic function with either fractional
area change or TAPSE, should be performed.44
Overall, echocardiography can play an important role in the
pregnant patient with PH. In this patient, echocardiography
facilitated the diagnosis of PH and allowed for monitoring
before and after the cesarean section. While it certainly can be
an asset, anesthesiologists should bear in mind that pregnancy
results in a variety of physiologic adaptations, which can be
apparent on echocardiography. Knowledge of these changes
during pregnancy allows the echocardiographer to interpret
unexpected findings within the appropriate context. Ultimately, this can lead to improved decision-making and allow
for optimization of the patient’s clinical care.
In summary, this case conference highlights the management of a complex patient with a high-risk pregnancy. Because
PH can confer significant morbidity and mortality, it generally
is recommended that these patients avoid pregnancy due to the
additional stress from the physiologic changes that occur. In
this patient, however, it was not known that she had PH until
the pregnancy was well underway and the fetus already was
viable. There were several steps that were integral to ensuring
a successful outcome. First, the use of echocardiography to
investigate this patient’s symptoms ultimately led to the correct diagnosis. Second, the formation of a multidisciplinary
team involving the relevant clinicians was critical. This team
of providers included high-risk obstetrics, maternal-fetal medicine, heart failure and/or PH cardiology service line, cardiac
surgery, cardiac anesthesia, and obstetric anesthesia. The
expertise from these teams allowed for optimization of this
patient’s clinical status based on the known changes of pregnancy, formation of a unique treatment plan taking into
account medications that are contraindicated during pregnancy, and ensuring the ability to rapidly institute advanced
measures, such as ECMO, if necessary.
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